Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.

Trial Details

NCT ID
NCT07067268
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • Adjuvant therapy
Locations (sample)
  • Shanghai, China, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥18 years;
  • Histologically confirmed nasopharyngeal carcinoma;
  • Expected survival time ≥12 weeks;
  • ECOG performance status: 0-1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →